Presidential Realty Corp., a real estate investment trust based in White Plains, reported net income of 91 cents a share during the third quarter, compared to a net loss of 3 cents a share a year earlier. The most recent results included a gain of 81 cents per share from the sale of 42 cooperative apartment units at Towne House in New Rochelle and a gain of 2 cents per share from the sale of a cooperative apartment unit in New Haven, Conn.

Vision-Sciences Inc., an Orangeburg-based medical-device maker, reported a net loss of $2.5 million for its fiscal second quarter, or 7 cents a share, compared to a net loss of $1.3 million, or 4 cents a share, a year earlier. Sales of $3.05 million fell slightly from $3.13 million a year earlier.

Ron Hadani, president and chief executive officer, said that sales of the company’s medical scopes increased significantly during the quarter. He added that the company is “excited” about the growth of its urology video and fiber scope product lines.

The Center for Wound Healing Inc., a Tarrytown-based manager of wound care treatment centers, reported a net loss of $1.2 million, or 5 cents a share, during its fiscal first quarter, compared to a net loss of $1.1 million, or 5 cents a share a year earlier. Revenues surged 18 percent to $7.03 million.

Chief Executive Officer Andrew G. Barnett said the company has increased daily treatments at its centers and moved forward with plans to open three additional centers in the next 90 days.

General Bearing Corp., a West Nyack-based manufacturer of ball bearings, reported net income of $2.2 million for the third quarter, up from $1.9 milllion a year earlier. Earnings per share rose to 59 cents from 49 cents. Sales of $39.2 million increased from $31.9 million.

Nutrition 21 Inc., the Purchase-based company that markets nutritional supplements, said this morning it earned $200,000 during the first quarter of its fiscal 2009, its first profitable quarter in seven years.

The company lost $4.1 million in the first quarter of fiscal 2008.

Revenues rose to $12.7 million, from $12.2 million.

Michael Zeher, the company’s president and chief executive, said he was pleased with the results.

“Revenues were strong despite the current difficult economic conditions, and our net income was the first we’ve recorded since the first quarter of fiscal 2002,” he said.

He said the company expects to expand relationships with some of its retail customers and to introduce several new products the rest of the fiscal year.

Environmental Power Corp., a Tarrytown-based company that produces natural gas from animal waste and other organic materials, reported a net loss of $5.09 million, or 33 cents a share during the third quarter. That compared to a net loss of $6.25 million, or 61 cents a share, a year earlier. Revenues increased to $456,000 from $344,000 a year earlier. The company said that it is experiencing strong interest in its products due to increased focus on renewable sources of energy in many parts of the country.

Progenics Pharmaceuticals Inc., a biotech company based in Eastview, reported imporved results for the third quarter as it marked milestones for key medications, including a constipation treatment.

The net loss of $12.2 million during the third quarter narrowed from the net loss of $15.6 million a year earlier. Net loss per share of 41 cents improved from the net loss per share of 58 cents a year earlier. Revenues of $17.5 million increased from $17 million a year earlier as Progenics received payments from Wyeth related to the constipation drug Relistor that they are developing and commercializing.

“We have been able to maintain a healthy balance sheet while advancing our product pipeline because of the continued funding by Wyeth of our lead program, Relistor, together with payments for achieving milestones and royalties on commercial sales,” Chief Executive Officer Paul J. Maddon said in a written statement.

Maddon added that Progenics also is achieving success with a prostate cancer therapy, PSMA ADC, that has entered phase 1 testing.

WHX Corp., a White Plains-based industrial products manufacturer, reported net income of $9.5 million, or 55 cents a share, during the third quarter, compared to a net loss of $13.7 million, or $1.37 a share, a year earlier. Net sales of $199.8 million rose from $182.4 million a year earlier. WHX said the improved results reflected higher sales, improved operating efficiencies and a more profitable product mix.

Profits dropped 34 percent at Gamco Investors Inc. during the third quarter as the global financial crisis and one of the steepest stock market selloffs since the Great Depression hurt companies that manage investments.

Gamco, the Rye-based investment company founded by famed money manager Mario Gabelli, manages private investment accounts, mutual funds and offshore funds.

Gamco’s net income for the third quarter fell to $12 million from $18.3 million a year earlier. Earnings per share dropped to 43 cents from 64 cents. The company’s assets under management, $25.6 billion, were 19.1 percent below levels a year earlier.

Gamco, like most other asset managers, said it experienced net outflows of client assets during the third quarter. The outflows are occuring as nervous investors struggle with a challenging market environment that has pushed the S&P 500 index down nearly 37 percent for the year.

“Given global equity markets, we are strengthening our research, portfolio management and client service skill sets while rebalancing all non-investment related spending,” Chief Financial Officer Jeffrey M. Farber said in written statement.

EpiCept Corp., an early-stage Eastview pharmaceutical company, reported this morning that it lost $6.2 million, or 9 cents a share, in the third quarter, compared with a loss of $7.7 million, or 20 cents a share, last year.

Jack Talley, the president and chief executive of EpiCept, said the company focused during the quarter on getting regulatory approval in Europe to market Ceplene, a drug to prevent the relapse of a form of leukemia. The company got the approval last month.

“We have carefully controlled expenses this year in all areas of company operations,” he said. “Having secured European approval of Ceplene, the next key iutem has been advancing partnership dialogues for Ceplene marketing rights and preparing for a commercial launch as soon as possible in 2009.”

TAL International Group Inc., a Purchase-based lessor of intermodal freight containers, reported net income of $14.5 million, or 44 cents a share, during the third quarter, up from net income of $3.5 million, or 11 cents a share, a year earlier.

Leasing revenues for the third quarter were $80.4 million, up from $71.8 million a year earlier.

Brian M. Sondey, president and chief executive officer, said that TAL benefited from strong leasing revenues as customers picked up freight containers they had committed to lease in the first and second quarters.

Prestige Brands Holdings Inc., the Irvington company that markets Comet cleanser, Murine eye and ear drops and Prell shampoo, said today profits for its fiscal second quarter rose 25 percent to $8.5 million, or 17 cents a share, due to a reduction in interest expenses.

The company said interest expenses dropped by 30 percent because of a significant repayment of debt over the past year and lower interest rates.

During the second quarter of 2007, the company earned $6.8 million, or 14 cents a share.

Revenues rose 1 percent to $88.1 million in this year’s quarter, which ended in September. Operating income of $20.5 million was down from $20.6 million last year.

Visant Corp., a marketing and publishing services business in Armonk, reported a net loss of $1.9 million during the third quarter, compared to a net loss of $2.8 million a year earlier.

Net sales increased 8 percent to $256.7 million. Sales increased in business units that sell class rings and school yearbooks.

Marc Reisch, chairman and chief executive officer, said in a written statement that the company is focused on cutting costs in a slowing economy. “The significant cost savings from these consolidations will provide important cushion in this difficult economic environment,” he said.

Hudson Technologies Inc., a Pearl River-based refrigeration services company, reported net income of $2.7 million, or 14 cents a share during the third quarter, compared to net income of $357,000, or 2 cents a share, a year earlier. Revenues of $5.8 million jumped 23 percent from a year earlier, primarily due to increases in the sales price and pounds of refrigerant sold. The earnings for the quarter reflected an income tax benefit of nearly $2.4 million.

Elmsford-based pharmacy benefits manager BioScrip Inc. said it earned $1.4 million, or 4 cents a share, in the third quarter, a drop from the $1.7 million, which was also 4 cents a share, last year. Revenues rose to $359.4 million from $297.6 million.

This year’s results included a one-time charge of $795,000, or 2 cents a share, from a settlement with the U.S. Office of the Inspector General. The settlement related to conduct that began in 2003 and ended in late 2006, the company said.

Regeneron Pharmaceuticals Inc., a biotech company in Eastview, reported this morning that it lost $21.1 million, or 27 cents a share, in the third quarter, compared with a loss of $35.8 million, or 54 cents, last year.

Revenues rose to $65.6 million from $22.3 million. The company said its revenue was from research and development contracts, technology licensing and product sales.

Regeneron shares gained 20 cents in the opening minutes of trading this morning and were at $20.08. The shares are down about 16.9 percent on the year.

Acorda Therapeutics Inc., the Hawthorne company that sells a drug for people with multiple sclerosis, said this morning its third-quarter loss more than doubled to $18.9 million from $8.5 million last year.

On a per-share basis, the company lost 53 cents in the quarter that ended in September, compared with 30 cents last year.
Acorda, which markets the drug Zanaflex, said sales rose to $12.44 million from $10.44 million.

But the company pumped more money into its research and development efforts, spending $8.7 million, compared with $5.6 million last year. The company said the research and development expenses were related to its bid to market Fampridine-SR, a drug to help people with multiple sclerosis walk.

“We made significant progress this quarter in preparing a new drug application for Fampridine-SR, which we expect to submit electronically to the U.S. Food and Drug Administration in the first quarter of 2009,” Dr. Ron Cohen, the company’s president and chief executive, said in a statement released by the company. “We also concluded a series of meetings with four European regulatory agencies, and as a result are planning to file a marketing authorization application for Fampridine-SR in Europe in 2009.”

Acorda shares were at $21.79 in the early minutes of trading this morning, up 37 cents. On the year, the shares are down by less than 1 percent.

Net income surged 80 percent at Universal American Corp. during the third quarter as the Rye Brook-based health insurer enrolled more members in its health insurance plans and withstood losses on troubled investments.

Net income of $48.8 million, or 56 cents a share, jumped from net income of $27.1 million, or 40 cents a share a year earlier. Revenues increased 48.7 percent to $1.1 billion, including a revenue boost from the company’s 2007 purchase of MemberHealth Inc. of Cleveland.

Richard Barasch, chairman and chief executive officer, said the company benefited from membership growth of 16.4 percent in its Medicare Advantage HMO business, including an increase of 183 percent in Oklahoma, Dallas and Milwaukee.

Universal American also reported higher profits and revenues in its Medicare Part D business covered under the federal government program that provides prescription drug benefits for senior citizens.

The global financial crisis affected the company through pre-tax losses and impairments of $12.1 million on its its investments, or 1.1 percent of its investment portfolio. The company disclosed that it has been hurt by exposure to troubled subprime mortgage investments and Lehman Brothers, the Manhattan-based investment bank that filed for bankruptcy earlier this year.

“Over the past several months, we have adopted a more conservative approach to our investment portfolio, which focuses more on capital preservation than on generation of investment yield,” Barasch said.

Spar Group Inc., a marketing company based in Tarrytown, reported a net loss of $117,000, or 1 cent per share during the third quarter, an improvement from a net loss of $1.7 million, or 9 cents per share, a year earlier.

Net revenues for the quarter rose 20 percent to $17.3 million from $14.4 million a year ago.

Gary Raymond, president and chief executive officer, said that the results reflect “stringent cost controls” and “positive momentum” in Spar’s international and domestic businesses.

Acadia Realty Trust, a real-estate investment trust based in White Plains, reported net income of $4.99 million, or 15 cents a share, during the third quarter, down from $8.49 million, or 26 cents a share, a year earlier.

Total revenues rose to $27.3 million from $23.9 million. Acadia’s properties include neighborhood and community shopping centers in major metropolitan areas.

“We are pleased with our current quarter results,” Kenneth F. Bernstein, president and chief executive officer, said in a written statement. “However, we are acutely aware of the current distress in the capital markets and the clear signs that the consumer is cutting back wherever possible. No business or portfolio is immune to these economic forces.”